Institute of Personalized Medicine - PUMA IPM

Pharmacogenomics aims at understanding how variations in the human genome affect the response to medications.

Our researchers are working to generate new knowledge, and to develop tools and algorithms that can help in personalizing medicine utilizing a patient’s genetic profile and other factors to achieve maximum therapeutic benefit with minimum toxicity.

Pharmacogenomics Conference

Genomic Testing to Individualize Drug Therapy

Registration Closed. Questions? Contact pgxconf@umn.edu
June 22, 2018  -  7am-5pm
McNamara Alumni Center
University of Minnesota

News

Jay Wen - web

Jay's research focuses on the determination of known genetic variations within Very Important Pharmacogenes (VIPs) in the Hmong population which brings local, state-wide and regional relevance to the nationally supported NIH “Precision Medicine Initiative”.

Robert Straka is a President's Community-Engaged Scholar Award Collegiate Recipient. View a video of his work in the Hmong community.

The 2nd annual Summit on Precision Medicine held on March 22, 2018 on the Duluth campus was a success.  This year the focus of the summit was on Precision Medicine in Native American and Rural Health.   

See the FOX21 story on how The School of Medicine at the University of Minnesota Duluth is discussing populations with health disparities.

Experts on campus are addressing how native american and rural communities could receive better medical attention.

Weekly Genomics Scan

This weekly update features emerging roles of human genomics, testing and interventions in a wide variety of noncommunicable diseases across the life span.

Health Impact Weekly Scan

Precision Medicine Seminar Series

"A Genetic Basis for Brain Size in Human Development"

William B. Dobyns, MD

Friday, June 1
2 PM - 3 PM
Special Location: 1-450 Moos Tower (TC); 302 Heller Hall (Duluth via ITV)

Dr. William B. Dobyns is Professor of Pediatrics (Genetics) and Neurology, University of Washington, and Principal Investigator in the Center for Integrative Brain Research at Seattle Children’s Research Institute. He is a physician-scientist trained in both pediatric neurology and medical genetics, and director of a molecular genetics laboratory that studies the nature and causes of numerous developmental brain disorders in children. While best known for studies of lissencephaly, his work has involved many different disorders including early childhood epilepsy, intellectual disability, autism, microcephaly and macrocephaly, many malformations of cortical development, malformations of the corpus callosum, brainstem and cerebellum, vascular malformations both in the brain and elsewhere, childhood stroke, and mosaicism as a mechanism of disease. 

This event is free and open to the public. Light refreshments will be served.

A Genetic Basis for Brain Size in Human Development Poster

CPIC Guideline Videos

See the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Videos, taken from the PharmGKB YouTube channel.

Codeine and CYP2D6

Clopidogrel and CYP2C19

Simvastatin and SLCO1B1

Phenytoin, HLA-B and CYP2C9

Carbamazepine and HLA-B

Allopurinol and HLA-B

Abacavir and HLA-B